Viewing nowCombinationTrusitam Tablets 50/1000 Milligrams (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boryung Co., Ltd.

MFDS item code 202204593 · Approved 2022.12.21 · Insurance code 641908200
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist patients with type 2 diabetes in controlling their blood sugar levels. It is particularly suitable for those who are also following dietary and exercise regimens, as sitagliptin and metformin work together to effectively manage blood sugar. This medication helps maintain stable blood glucose levels and can assist in preventing diabetes-related complications. Taking it consistently as part of your treatment plan will improve blood sugar control.
The dose of this drug for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this drug for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be conducted. Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication consists of two active ingredients, sitagliptin and metformin. Firstly, sitagliptin can, in rare cases, cause severe allergic reactions, which may include anaphylaxis, angioedema, and severe skin rashes or exfoliative skin diseases. If these symptoms occur, you must stop taking the medication immediately and consult your physician. Additionally, sitagliptin may cause acute pancreatitis, characterized by inflammation of the pancreas; if symptoms such as abdominal pain, severe nausea, or vomiting occur, notify healthcare professionals immediately. Metformin carries a risk of lactic acidosis, a rare but potentially life-threatening condition due to the excessive accumulation of lactate in the body leading to acidification of the blood. Symptoms include fatigue, muscle pain, breathing difficulties, and abdominal pain; seek medical attention immediately if these symptoms occur. Particularly, it is safer not to use this medication in patients with impaired kidney function, liver dysfunction, dehydration, severe infections, or cardiovascular diseases. The medication should not be administered to patients with moderate to severe renal impairment, acute heart failure, acute myocardial infarction, or to women who are pregnant or breastfeeding. While taking this medication, there may be symptoms of hypoglycemia, especially if used with other blood glucose-lowering agents or insulin. Blood sugar should be monitored regularly, and one should be alert to symptoms of hypoglycemia. Symptoms include dizziness, trembling, cold sweat, and headache. Upon onset of these symptoms, it is critical to consume sugar promptly. Additionally, it is advisable to avoid alcohol during the course of this medication, as it may increase the risk of lactic acidosis. If you are scheduled for surgery or a radiographic contrast examination, stop taking this medication temporarily before and after the test, and resume once kidney function has normalized. This medication should preferably not be used in children under 18 years of age, as safety and effectiveness have not been established in this age group. Elderly patients should have regular kidney function assessments, and doses should be adjusted accordingly as kidney function may decline. While taking this medication, if abnormal symptoms such as skin rash, severe joint pain, blistering skin diseases, acute shortness of breath, severe headaches, or dizziness occur, consult your physician immediately. Lastly, this medication should be taken safely under regular blood tests and kidney function assessments to monitor for adverse reactions and drug accumulation.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a sealed container to prevent exposure to air or moisture. It is best to maintain the storage temperature between 1 degree and 30 degrees Celsius at room temperature.
Dark red oval film-coated tablets
56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boryung Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.